Guided Therapeutics (GTHP) Cash from Financing Activities (2011 - 2025)

Guided Therapeutics has disclosed Cash from Financing Activities across 15 years of filings, most recently posting $267000.0 for Q4 2025.

• Cash from Financing Activities for Q4 2025 came in at $267000.0, down 49.24% year-over-year; the trailing twelve-month figure through Dec 2025 was $745000.0 (down 18.67% YoY), and the FY2025 annual result was $745000.0, down 18.67% from the prior year.
• Cash from Financing Activities came in at $267000.0 for Q4 2025 at Guided Therapeutics, up from $181000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $2.9 million in Q3 2022 to a low of -$154000.0 in Q3 2023.
• The 5-year median for Cash from Financing Activities is $188500.0 (2023), against an average of $346600.0.
• Across the five-year window, Cash from Financing Activities soared 687.88% in 2022 and plunged 300.0% in 2024, its largest moves.
• Guided Therapeutics' Cash from Financing Activities stood at -$53000.0 in 2021, then gained by 20.75% to -$42000.0 in 2022, then soared by 566.67% to $196000.0 in 2023, then surged by 168.37% to $526000.0 in 2024, then plunged by 49.24% to $267000.0 in 2025.
• The last three Cash from Financing Activities figures came in at $267000.0 (Q4 2025), $181000.0 (Q3 2025), and $239000.0 (Q2 2025), per Business Quant data.